On Nov 01, major Wall Street analysts update their ratings for $Merck & Co (MRK.US)$, with price targets ranging from $110 to $150.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and adjusts the target price from $130 to $123.
BofA Securities analyst Charlie CY Yang maintains with a buy rating, and sets the target price at $120.
Wells Fargo analyst Mohit Bansal maintains with a hold rating, and adjusts the target price from $125 to $110.
BMO Capital analyst Evan Seigerman maintains with a buy rating, and maintains the target price at $150.
Furthermore, according to the comprehensive report, the opinions of $Merck & Co (MRK.US)$'s main analysts recently are as follows:
The recent quarterly report underscored persistent uncertainties surrounding Gardasil and the market in China as we approach 2024. Following the third-quarter earnings surpassing expectations and guidance being largely sustained, estimates have been adjusted accordingly.
Merck's Q3 results exhibited a modest surpass in both revenue and earnings, however, the stock experienced a slight decline as the company fine-tuned its revenue outlook and reduced its EPS projections to account for charges associated with previous acquisitions. While revenue forecasts for 2024 remain largely unaltered and EPS estimates show a minor increase, projections for 2025 have been adjusted downwards due to anticipated reductions in Gardasil sales and heightened operational expenditures.
Merck's adjustment of its Gardasil expectations represents a positive direction. However, the introduction of new investments may require a change in narrative, and it's uncertain if Winrevair alone will be sufficient to initiate this shift, according to an analyst's research note.
Here are the latest investment ratings and price targets for $Merck & Co (MRK.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月1日，多家華爾街大行更新了$默沙東 (MRK.US)$的評級，目標價介於110美元至150美元。
摩根士丹利分析師Terence Flynn維持持有評級，並將目標價從130美元下調至123美元。
美銀證券分析師Charlie CY Yang維持買入評級，目標價120美元。
富國集團分析師Mohit Bansal維持持有評級，並將目標價從125美元下調至110美元。
BMO資本市場分析師Evan Seigerman維持買入評級，維持目標價150美元。
此外，綜合報道，$默沙東 (MRK.US)$近期主要分析師觀點如下：
最近的季度報告突顯我們在逼近2024年時圍繞着Gardasil和中國市場的持續不確定性。隨着第三季度盈利超出預期並且指引大體維持穩定，相應的預估已做出調整。
默沙東的第三季度業績在營業收入和每股收益方面略有超過，然而股價出現輕微下滑，因爲公司調整了營業收入展望，並降低了每股收益預期，以考慮與先前收購相關的費用。儘管2024年的營業收入預測基本未變，每股收益估計有輕微增加，但由於預期Gardasil銷售減少和運營支出增加，2025年的預測已進行下調。
默沙東調整Gardasil的預期代表着一個積極的方向。然而，新投資的引入可能需要改變敘事，根據分析師研究報告，目前不確定Winrevair是否單獨足以啓動這一轉變。
以下爲今日4位分析師對$默沙東 (MRK.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
